Wyeth says that it has assumed all marketing and distribution rights to the anticoagulant treatment BeneFIX in Europe for patients with haemophilia B. Wyeth says that it has assumed all marketing and ...
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe ...
Findings of a late-stage study show back the use of once-weekly treatment with Pfizer’s BeneFix to cut down bleeding episodes in patients with haemophilia B. Findings of a late-stage study show back ...
Enhancements Provide Haemophilia B Patients with a Simpler and More Convenient Preparation Process for Recombinant Factor IX MAIDENHEAD, England, August 20 -- Wyeth Pharmaceuticals, a division of ...
Credit: Getty Images. The Agency stated that it “erred in approving the indication for routine prophylaxis in children with hemophilia B” due to the Orphan Drug exclusivity. The Food and Drug ...
Co announces it has received approval from the FDA for new product enhancements for BeneFIX Coagulation Factor IX that will offer patients a simpler and more convenient preparation process compared ...
Following are specific recommended plasma levels and actions for common bleeding problems and clinical situations which occur with Hemophilia B, also known as Factor IX Deficiency: Assess situation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results